Table 3 ICURs – base-case scenario and ten-year time horizon scenario / 1,000 individuals
From: Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada
| Â | Costs ($) | Incremental costs ($) | QALYs | Incremental QALYs | ICUR ($/QALY) |
|---|---|---|---|---|---|
MoH perspective | |||||
Base-case scenario | |||||
Olanzapine | 9,729,158 | -3,847,300 | 3,301 | 84.84 | dominant |
Asenapine (Saphris®) | 5,881,858 |  | 3,386 |  |  |
Ten-year time horizon scenario | |||||
Olanzapine | 18,233,001 | -6,956,705 | 5,784 | 160.67 | dominant |
Asenapine (Saphris®) | 11,276,296 |  | 5,945 |  |  |
Societal perspective | |||||
Base-case scenario | |||||
Olanzapine | 11,466,846 | -3,878,343 | 3,301 | 84.84 | dominant |
Asenapine (Saphris®) | 7,588,702 |  | 3,386 |  |  |
Ten-year time horizon scenario | |||||
Olanzapine | 22,527,000 | -7,131,099 | 5,784 | 160.67 | dominant |
Asenapine (Saphris®) | 15,395,901 |  | 5,945 |  |  |